Michael Rawlins

Prospect Magazine

Michael Rawlins

/ / Leave a comment

The chairman of Nice—the body that decides which drugs the NHS can afford—on the Herceptin row, how Nice calculates the value of a human life and the pharmaceutical industry’s expensive drugs crisis

Since it was set up in 1999, the National Institute for Health and Clinical Excellence, or Nice, has rarely been out of the news. Turn to one newspaper and it is “the government’s drug rationing watchdog,” denying suffering patients access to drugs in order to save the NHS a few miserable pounds. Turn elsewhere and Nice is a brave attempt to bring rationality and best practice into the provision of healthcare.

When it opened for business (then just called the National Institute for Clinical Excellence) provision of healthcare in Britain was subject to a postcode lottery, with different drugs and treatments available in different regions (as it remains today). There was no way to evaluate what worked best, and there were often failures to speedily introduce new drugs and best practice. Nice was established to remove these inequalities and inefficiencies by providing “clear and robust advice” to NHS staff.


You need to be logged in to see this part of the content. Please either subscribe or Login to access.

Leave a comment


Alun Anderson

Alun Anderson is a former editor-in-chief of New Scientist 

Share this

Most Read

Prospect Buzz

  • Prospect's masterful crossword setter Didymus gets a shout-out in the Guardian
  • The Telegraph reports on Nigel Farage's article on Lords reform
  • Prospect writer Mark Kitto is profiled in the New York Times

Prospect Reads

  • Do China’s youth care about politics? asks Alec Ash
  • Joanna Biggs on Facebook and feminism
  • Boris Berezosky was a brilliant man, says Keith Gessen—but he nearly destroyed Russia